Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and Forecast 2024-2033| Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd

Overview and Scope

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain

Sizing and Forecast

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $16.6 billion in 2023 to $17.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $23.11 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Segmentation & Regional Insights

The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2023. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

Major Driver Impacting Market Growth

The increase in the menopause population is expected to propel the growth of the vasomotor menopausal symptoms treatment market going forward. Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is a significant life stage that typically occurs in women between the ages of 45 and 55, with the average age being around 51. The rising number of menopausal women, which demands treatment for hot flashes and vaginal dryness globally, is one of the primary factors pushing the growth of vasomotor menopausal symptoms (VMS) treatment. For instance, in November 2022, according to the Cuyuna Regional Medical Center, a US-based organization, estimated that by 2025, 1.1 billion women will be menopausal due to women living longer. Moreover, the population of menopausal will be increased by 1.6% annually until 2060. Therefore, the increase in the menopause population is driving the growth of the vasomotor menopausal symptoms treatment market.

Key Industry Players

Major players in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

The vasomotor menopausal symptoms (vms) treatment market report table of contents includes:

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market – Macro Economic Scenario

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and Growth

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

Top Major Players: